DATA GRAPHICS | Data Byte
Chinese biotechs remain a rich source of ADC deals
Western biotechs have struck at least 10 licensing deals to gain antibody-drug conjugate technology from China since the start of 2022
April 13, 2023 11:05 PM UTC
Western companies have increasingly reached into China to strike deals for ADCs, furthering the reach of platforms, technologies and programs originating in that country and bringing them to the rest of the world.
Since the start of 2022, Chinese biotechs have entered at least 10 deals and collaborations that will give Western biopharmas access to antibody-drug conjugate technologies or programs, some of which have already reached the clinic...